ADC man­u­fac­tur­ing will like­ly stay with es­tab­lished CD­MOs due to high bar­ri­er to mar­ket en­try

An­ti­body-drug con­ju­gate (AD­Cs) man­u­fac­tur­ing is like­ly to re­main among CD­MOs al­ready mak­ing them due to de­mand­ing mar­ket en­try re­quire­ments, ex­ec­u­tives in the ADC space said. ADC tox­i­c­i­ty re­quires ex­tra care in pro­duc­tion, with staff train­ing and equip­ment need­ed be­yond tra­di­tion­al man­u­fac­tur­ing for chemother­a­pies and an­ti­bod­ies, they added.

“CD­MOs of all sizes prob­a­bly see the cur­rent mar­ket po­ten­tial for de­vel­op­ment and man­u­fac­ture of AD­Cs, but the abil­i­ty to en­ter the space ef­fi­cient­ly is lim­it­ed for many,” added Roger Lias, CCO at Au­ri­gene Phar­ma­ceu­ti­cal Ser­vices, a CD­MO with ADC man­u­fac­tur­ing abil­i­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER